Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-21-048695
Filing Date
2021-07-29
Accepted
2021-07-29 19:36:25
Documents
2
Period of Report
2021-07-29

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 3664
2 POA DOCUMENT poa.txt EX-24.3_1001104 2037
  Complete submission text file 0001209191-21-048695.txt   7102
Mailing Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142
Business Address
Stehman-Breen Catherine (Reporting) CIK: 0001702233 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40656 | Film No.: 211129341

Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Issuer) CIK: 0001858848 (see all company filings)

EIN.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)